We are proud to support clients who are at the forefront of innovative medicine. Their objectives are to discover, develop, and commercialize innovations that will significantly improve human health.
"AmideBio has been working with the Fleming CFO team for over 2 years - first with Gavin Maitland and then with Derek Watson. The forecasting, analysis and budgeting support has been very helpful indeed. More importantly, they have become an integral part of the business - a true partner to the CEO of a start-up company. Indeed, the "fractional" in their description is in name alone - they feel like an essential member of the leadership team. "
- Pawel Fludzinski, PhD
CEO & President, AmideBio
"I have worked with Gavin Maitland from Fleming CFO since the founding of Ceria Therapeutics three years ago. Not only was he able to help us rapidly and efficiently solve our basic finance and accounting needs, but he built our budgets and cash forecasts to meet the expectations of our external investors. In addition to his role as CFO, he has been an integral part of our management team as the company raised additional funding and advances towards IND."
- Kenneth W. Liechty, MD
Founder/President, Ceria Therapeutics, Inc.
"As a small startup we needed fractional CFO support early on, and both Gavin Maitland and Carrie Showalter quickly became part of the team. They are professional, knowledgeable of the space, and they have kept our business growing. I would highly recommend working with Fleming CFO for any life science company needing high quality CFO services at an affordable price. "
- Heather Underwood, PhD
CEO, EvoEndo, Inc.
We worked with a pre-clinical drug discovery company with Series A funding to put in place financial and reporting controls. We cleaned up the financial statements, figured out the cap table, implemented internal financial controls and a detailed monthly Board Report. We implemented a cash forecast to get a true reading on the cash runway.
We worked with an early stage Artificial Intelligence analytics company. We recast (revamped) the statement of operations into categories that made sense for their business, built a P&L to allow the full team to make better decisions. We implemented a tight monthly financial close in conjunction with a detailed operating budget for actual vs. budget revenue and cost analysis.
We worked with a Series B funded medical device company to develop and implement a detailed multi-year monthly operating budget. The budget was integral to the planning for the transition from pre-clinical R&D through to Phase 1/2 clinical studies. Worked with all members of the executive management team to ensure long-term buy-in and focus.